Comparing Platelet Rich Plasma and Corticosteroid for Military & Civilian Patients With Glenohumeral Osteoarthritis
A legfontosabb adatok
- Ki végzi
- Walter Reed National Military Medical Center
- Hol
- Bethesda (Egyesült Államok)A helyszín megnézése
- Azonosító
- Állapot
- Befejeződött
- Fázis
- 3. fázis
- Résztvevők
- 50 fő vett részt
- Kezdés
- 2022. szept. 26.
- Befejezés
- 2025. máj. 8.
- A vizsgálat típusa
- Beavatkozással járó, 3 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Platelet Rich Plasma Injection
- Corticosteroid Injection
- Delayed Platelet Rich Plasma Injection After Corticosteroid Injection Failure
- A regiszteradat frissítve
- 2025. szeptember 23.
Ki vehet részt
- Életkor
- 18 év – 70 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 17 feltétel megnézéseKevesebb
Ki vehet részt
- DEERS eligible
- Male or female, aged 18 to 70 years (inclusive)
- Presenting symptoms of shoulder pain caused by mild to moderate Shoulder OA as defined by Samilson Prieto criteria on a standard anterior-posterior (AP) Xray series
- BMI < 40
- Willing and able to give voluntary informed consent to participate in this investigation
- Glenohumeral joint osteoarthritis that has been refractory to standard care treatments
Ki nem vehet részt
- Patients who have received shoulder intraarticular or subacromial injection(s) in the last 3 months
- Patients who have undergone arthroscopic surgery on the study shoulder within the past year
- Patients who have had an adverse reaction to a previous corticosteroid or PRP injection either documented in the medical record or shared by the patient during screening
- Diabetes (Type 1 or II)
- Fibromyalgia or chronic fatigue syndrome
- Any other serious medical condition(s) that might preclude optimal outcome and/or interfere with participation such as intra-articular sepsis, bacteremia, fracture, joint instability, rheumatoid arthritis, osteoporosis, cancer, and coagulopathy
- Patients who have undergone arthroplasty on the study shoulder
- Inflammatory arthropathies
- Female patient who is pregnant or nursing
- Patients taking narcotics
- Patients with planned deployment or separation from the military within 12 months
Helyszínek itt: Egyesült Államok
- Walter Reed National Military Medical CenterBethesda, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
Shoulder arthroplasty provides successful improvement in pain and function for the treatment of end stage osteoarthritis (OA) of the shoulder in the older patient population (Sanchez 2008, Sampson 2010, Kon 2012, Fitzpatrick 2017). However, the optimal non-operative treatment for shoulder OA in the young active duty and civilian populations has yet to be determined. Although corticosteroid injections (CSI) are a viable option with diagnostic and short-term therapeutic benefit in glenohumeral OA, steroid does little to address the underlying pathology and confers risk of adjacent tendon failure (Kon 2009, Gosens 2011, Monto 2014, Tietze 2014). Platelet-rich plasma (PRP) derived from autologous blood, however, has the potential to enhance soft tissue healing as previously observed in muscles and tendons (Sanchez 2005, Randelli 2008, Hall 2009). PRP contains growth factors purported to safely facilitate local tissue regeneration as corroborated in multiple clinical studies investigating tendinopathy (Virchenko 2006, Kesikburun 2013, Fitzpatrick 2017, Schwitzguebel 2019). PRP is a promising concept to bridge the gap between conventional non-operative measures and surgical arthroscopy or arthroplasty options in a high functioning patient population with refractory disease. However, clinical literature elucidating the effects of intra-articular leukocyte-poor PRP (LP-PRP) injections in large joint degenerative OA has been slower to emerge, lacking substantiated data due to small sample sizes and treatment variability. Therefore, high level evidence-based studies remain critical in ascertaining the therapeutic value and clinical efficacy of LP-PRP in glenohumeral OA in order to establish standard of care protocols and guide systematic implementation.
A vizsgálat 3 csoportja
- Platelet Rich Plasma Injection GroupA vizsgált kezelés
Minimum 2cc Leukocyte Poor Platelet Rich Plasma
Kezelés: Platelet Rich Plasma Injection
- Corticosteroid Injection GroupMár használt kezelés, összehasonlításként
5cc Normal Saline + 2cc 10 mg/ml Triamcinolone Acetonide (Kenalog)
Kezelés: Corticosteroid Injection
- Delayed Platelet Rich Plasma Injection Group upon Corticosteroid Injection FailureA vizsgált kezelés
If a participant does not have any benefit from the corticosteroid injection by the six-week follow-up time point, then that participant will be eligible for a platelet rich plasma injection.
Kezelés: Delayed Platelet Rich Plasma Injection After Corticosteroid Injection Failure
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Prospective, Single-blind, Randomized, Multi-Center Study Comparing Platelet Rich Plasma and Corticosteroid for Patients With Glenohumeral Osteoarthritis in the Military and Civilian Population
- A regiszteradat frissítve
- 2025. szeptember 23.